• Abstract Submission Opens:
    • Session Abstracts (Issue Panel/Workshop/Other Breakout Sessions): Thursday, October 5, 2023
    • Research and Case Study Abstracts: Thursday,November 2, 2023
  • Abstract Submission Deadline:
    • Session Abstracts (Issue Panel/Workshop/Other Breakout Sessions): Thursday, December 14, 2023
    • Research and Case Study Abstracts: Sunday, January 14, 2024
  • Acceptance Notification:
    • Session Abstracts (Issue Panel/Workshop/Other Breakout Sessions): Week of Monday, January 29, 2024
    • Research and Case Study Abstracts: Week of Monday, February 26, 2024


  • Abstract submissions are invited for Research, Case Study, Issue Panel, Workshop, and Other Breakout Session abstracts.
  • All research, case study, issue panel, workshop, and other breakout session submissions and presentations must be in English.
  • All research, case study, issue panel, workshop, and other breakout session submissions and presentations must not promote any product or service.
  • Registration is required for all presenters.
  • Expenses associated with submissions and presentations are the responsibility of the presenter.
  • The presenters of research are required to disclose financial support. Abstract review will NOT be based on this information.
  • Submitting authors/submitters must agree to disclose AI-Assisted Content in the submission form. Failure to disclose in submissions and/or accepted materials may result in its withdrawal from ISPOR.
  • ISPOR does not accept abstracts that have been previously presented at another meeting and/or previously published (either in print or online) by another Society or journal. Research presented at a previous ISPOR meeting is also not allowed. View ISPOR's abstract policy here.

Delivery of Sessions
ISPOR 2024 will be held live, in-person on May 5- 8, 2024, at the Georgia World Congress Center, Atlanta, GA, USA.

Joint Clinical Assessment/Scientific Advice in the EU
(For Issue Panel, Workshop, Other Breakout Sessions Only)
Given the ongoing development of the Joint Clinical Assessment process in the EU and the accompanying methods guidance, we anticipate that this will be a highly relevant topic at ISPOR 2024. Similarly, Joint Scientific Consultations constitute an integral part of the EU HTA regulation and provide an opportunity to discuss the development plan to generate evidence to meet the needs of both regulators and HTA bodies with regards to pharmaceuticals and medical devices.

Sessions specifically relevant to either the process or methods involved in these areas, especially the more controversial aspects, will be highlighted in our program.

ISPOR's Diversity Policy and Strategic Plan

ISPOR is strongly committed to diversity. The Society's Strategic Plan and core values embrace excellence through encouragement and acceptance of diverse ideas, cultures, and disciplines. Research submissions are encouraged from all stakeholders and are evaluated based on merit. ISPOR also aims to reflect the diversity of its membership in all endeavors and encourages consideration of diversity in abstract submissions. Diversity dimensions include (but not limited to) gender, career stage, ethnicity, race, education, sexual orientation, region/geographic location, physical disability, and religion. Additional information can be found at the Society's Diversity Policy.


All abstracts must be submitted through ISPOR's online abstract system via the appropriate button on the right side of this page.


Please consider updated submission criteria when completing your submission.


  • Accepted research abstracts will be published as submitted in Value in Health. Changes to abstracts will not be accepted after the Submission Deadline; therefore, they should be carefully written and edited prior to submission.
    • Please note that only presented research will be published in Value in Health.
    • We strongly urge you to compose your proposal prior to starting a submission in the system.
    • Check the spelling of your abstract and title carefully.
  • Length of abstract: 300 words
  • Include e-mail addresses for all presenters.
    • Only the presenting author will receive all communications from ISPOR.
  • The use of tables and graphs in your research abstract or session proposal submissions are not allowed.
  • Generic names should be used for technologies (drugs, devices), not tradenames.
  • Multiple abstracts on the same study are discouraged.
  • Do not submit duplicate abstracts.
  • Do you indemnify ISPOR from any claims arising from this material?
  • Still have questions? Please reach out to us at conferences@ispor.org


New Submissions Closed

New Submissions Closed

New Submissions Closed

New Submissions Closed

New Submissions Closed

View, Resume, Edit or Withdraw a Submission